Iron supplementation in preterm infants treated by recombinant human erythropoietin.

Anemia in premature infants can be prevented by prophylactic treatment with recombinant human erythroprotein (r-huEPO). r-HuEPO as been used for a lon time in patients wit end-stage renal failure. The main factor which can li mit r-HuEPO efficiency is limited iron bioavailability. Adapted iron supple mentation is needed when preterm infants receive r-HuEPO in order to avoid the depletion of iron stores. Oral iron supplementation is simple but indig estibility is frequent. Furthermore, the intestinal absorption and utilizat ion of oral iron is limited. Parenteral iron supplementation is possible in infants who ar very pre-trm as they are parenterally fed during the first weeks of life. There are various preparations of intravenous iron with diff erent physicochemical properties. Toxicity and side-effects of parenteral i ron preparations depend on these properties. Two parenteral iron preparatio ns are available in France: iron-saccharate (Venofer(R)) andiron-dextrin (M altofer(R)). Iron delivery and possible side-effects of these preparations are different and need to be considered before use in preterm infants. (C) 1999 Elsevier Paris.